Figure 4. The protective effects of 17DMAG in cachectic muscle
wasting in C26 tumor-bearing mice.
(a) Left part : Bodyweight changes in normal control mice,
17DMAG or PU-H71-treated C26 tumor-bearing mice; veh1(17DMAG solvent) or
veh2(PU-H71 solvent) treated C26 tumor-bearing mice. Day 0: tumor
implantation. Day 7: 17DMAG injection began. Day 15: Terminal sacrifice
day. Right part : Another experiment for survival rates of
C26-tumor-bearing mice that received the treatment of 17DMAG or PU-H71
and their vehicle control. (b) Representative images of the
hindlimbs of normal (left), C26 tumor-bearing (middle), and
17DMAG-treated C26 tumor-bearing (right) mice. (c) Grip
strength was measured on day 14. (d) Tumor-free body mass, lean
mass weight, and the tibialis anterior (TA), gastrocnemius (Gastroc),
soleus, and extensor digitorum longus (EDL) muscles were weighed and
compared after dissection with an electronic scale; Data represent the
mean ± standard deviation (SD). *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 denotes 17DMAG vs. C26;
#p<0.05, ##p<0.01, ###p<0.001
denotes C26 vs. control.